Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.

IA, AlSharoqi; M, Aljumah; S, Bohlega; C, Boz; A, Daif; S, El-Koussa; J, Inshasi; M, Kurtuncu; T, Müller; C, Retief; MA, Sahraian; V, Shaygannejad; I, Slassi; K, Taha; M, Zakaria; PS, Sørensen

doi:10.1007/s40120-020-00187-3

Public

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review.

Shared by NobleBlocks on Apr 15, 2020 • 12:00 AM UTC

Authors:

AlSharoqi IA

Aljumah M

Bohlega S

Abstract

The majority of disease-modifying drugs (DMDs) available for the management of active relapsing-remitting multiple sclerosis (RMS) depend on continuous drug intake for maintained efficacy, with escalation to a more active drug when an unacceptable level of disease activity returns. Among continuousl...

Subject

Multiple sclerosis

Maintenance Therapy

Escalation Therapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!